Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.

@article{Delgado2004Cyclooxygenase2IT,
  title={Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure.},
  author={Reynolds M. Delgado and Mohamad A Nawar and Aly M Zewail and Biswajit Kar and William K. Vaughn and Kenneth K. Wu and Nena Aleksic and Natarajan Sivasubramanian and Kathleen McKay and Douglas L. Mann and James T. Willerson},
  journal={Circulation},
  year={2004},
  volume={109 11},
  pages={1428-33}
}
BACKGROUND Progression of heart failure after initial myocardial injury is mediated in part by various redundant inflammatory mediators, including the widely expressed cyclooxygenase-2 (COX-2). Because COX-2 inhibitors are useful in treating many inflammation-mediated diseases, we asked whether COX-2 inhibition can attenuate heart failure progression. METHODS AND RESULTS Heart failure was experimentally induced in 100 mice by administration of doxorubicin (4 mg. kg(-1). wk(-1) for 6 weeks… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology • 2001

Selective cyclooxygenase-2 inhibitors.

Rheumatic diseases clinics of North America • 1999

Congestive heart failure: when to consider new therapies

RM Delgado, EK Massin
Managed Care Interface • 1998

Similar Papers

Loading similar papers…